Illumina, Inc. (ILMN), Tuesday announced that the Centers for Medicare and Medicaid Services or CMS has granted reimbursement for the company's FDA-approved in vitro diagnostic TruSight Oncology Comprehensive test at the rate of $2,989.55 per test.
The move would help expand access to comprehensive genomic profiling and help healthcare providers to deliver precision oncology insights.
Starting January 1, 2026, TSO Comprehensive is reimbursed under the Clinical Laboratory Fee Schedule using Proprietary Laboratory Analysis code 0543U.
Currently, ILMN is trading at $137.00, down 3.24 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.